Arch Biopartners Inc.
ARCH.V
TSX
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.36M | 1.46M | 1.82M | 1.74M | 752.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.36M | 1.46M | 1.82M | 1.74M | 752.40K |
| Cost of Revenue | 1.33M | 1.55M | 2.63M | 2.45M | 1.19M |
| Gross Profit | 26.80K | -91.70K | -808.90K | -711.00K | -438.70K |
| SG&A Expenses | 1.09M | 2.04M | 1.97M | 1.86M | 1.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.42M | 3.59M | 4.61M | 4.31M | 3.03M |
| Operating Income | -1.06M | -2.13M | -2.78M | -2.57M | -2.28M |
| Income Before Tax | -1.44M | -2.45M | -3.02M | -2.88M | -3.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.44 | -2.45 | -3.02 | -2.88 | -3.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.44M | -2.45M | -3.02M | -2.88M | -3.57M |
| EBIT | -1.06M | -2.13M | -2.78M | -2.57M | -2.28M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.02 | -0.04 | -0.05 | -0.05 | -0.06 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.03 | -0.03 | -0.04 |
| EPS Diluted | -0.02 | -0.04 | -0.05 | -0.05 | -0.06 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.03 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 249.92M | 249.80M | 249.62M | 249.40M | 247.18M |
| Average Diluted Shares Outstanding | 249.92M | 249.80M | 249.62M | 249.40M | 247.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
